BECTON DICKINSON & CO

31 ago 2026

• Benzinga13:39
  B of A Securities Maintains Neutral on Becton Dickinson, Raises Price Target to $200

  B of A Securities analyst Travis Steed maintains Becton Dickinson (NYSE:BDX) with a Neutral and raises the price target from $185 to $200.

27 ago 2026

• Yahoo11:50
  BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation

  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients treated across 33 active U.S. sites, triggering the first planned interim analysis. This milestone places enr

26 ago 2026

• Yahoo21:15
  BD to Present at Wells Fargo 21st Annual Healthcare Conference

  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. Eastern Time.

22 ago 2026

• Yahoo00:10
  Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends

  Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...

21 ago 2026

• Yahoo23:11
  Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks

  Becton Dickinson stock has delivered a 25.4% return over the past year, while current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. Over the last 12 months, Becton Dickinson has returned 25.4%, which puts recent gains in focus when assessing how much upside may remain. Progress on the PREVENT clinical trial can support long term cash flow expectations, while the recent recall of...

• Yahoo12:10
  Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh

  Becton Dickinson (NYSE:BDX) reported completion of patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for prevention of incisional hernias. The large scale study is designed to assess the safety and effectiveness of Phasix Mesh as a prophylactic option in patients undergoing abdominal surgery. Finishing enrollment moves the trial closer to data readout and potential regulatory review for what the company positions as a first of its kind product in this category. The...

20 ago 2026

• Yahoo17:23
  BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study

  BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.

19 ago 2026

• Benzinga13:29
  What's Going On With Becton Dickinson Stock Wednesday?

  FDA alerts Becton Dickinson customers to remove recalled Huons sodium chloride ampules from convenience kits. No injuries reported.

18 ago 2026

• Benzinga16:26
  FDA Issues Early Alert For High-Risk Issue With Becton Dickinson Convenience Kits; Becton Dickinson Advises Removal Of Recalled Components From Convenience Kits; Warns Against Use Of Sodium Chloride Ampules In Affected Bd Kits

  https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-convenience-kit-issue-becton-dickinson

17 ago 2026

• Yahoo20:30
  BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire

  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.

• Yahoo15:49
  Are Wall Street Analysts Predicting Becton, Dickinson and Company Stock Will Climb or Sink?

  Becton, Dickinson and Company has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

13 ago 2026

• Yahoo18:44
  Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH

  Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.

• SeekingAlpha14:13
  Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing

  Becton Dickinson’s buy rating is reaffirmed as its clinical portfolio grows, Fitch improves risk, and stock momentum returns—get the latest Wall St view.